News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

04/20/2021 | Ovesco Endoscopy AG

FTRD®: international study shows favorable safety profile and efficacy of EFTR in the upper gastrointestinal tract

FTRD application in 56 patients with lesions in the upper GI tract showed a technical success rate of 93 %, a R0-resection rate of 68 % and only mild to moderate adverse ...
04/19/2021 | CureVac AG

CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic

Rolling submission to accelerate time to marketing authorization of CVnCoV in Switzerland Review process started with submission of first CVnCoV data package ...
04/15/2021 | CureVac AG

CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020

COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rollin...
[DE Copy] An X-ray image of a person's upper body is shown, in which individual vertebral bodies have been marked in color.

AIQNET - digital ecosystem to participate

On April 14th, 65 participants from the fields of clinics, research, software development and medical technology came together to get to know AIQNET and the partners involved better.

Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19

Charité – Universitätsmedizin Berlin, Germany, enrolls first patient in Phase II study to assess oral treatment ATR-002 RESPIRE1  is a placebo-controlled, inter...

Atriva Therapeutics Announces Changes to Management in COVID-19

Olaf Althaus appointed Chief Financial Officer Stephan Stenglein, M.D., recently joined as Chief Medical Officer Proven track record and 20+ years of experience in their respective fields of ex...

Insilico and 2-control ApS are Joining Forces to Create a New Industry 4.0 Solution

(Stuttgart) - Insilico Biotechnology AG and 2-control ApS are joining forces to take another important step towards the Smart Biofactory. The aim of the collaboration is ...
03/23/2021 | CureVac AG

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variant CVnCoV induces robust antibody titers with v...
03/22/2021 | CureVac AG

CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification and Efficacy Secondary Endpoint to Phase 2a

Impact of new SARS-CoV-2 variants supports specification of select strains for anticipated case-driven interim analysis in pivotal Phase 2b/3 study Progress in Phase...
03/18/2021 | Codex4SMEs

SMEs meet pharma with Codex4SMEs

On March 12th, 2021, an online round table with Sanofi took place in the context of the project Codex4SMEs (Companion Diagnostics expedited for small and medium-sized enterprises).   ...
03/17/2021 | Immatics

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Company to host conference call on Wednesday, March 17 at 8:30 am EST First anti-tumor activity observed in heavily pre-treated solid cancer patients during early p...
03/04/2021 | CureVac AG

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

Novartis plans to start manufacturing of the mRNA and bulk drug product of CureVac’s COVID-19 vaccine candidate, CVnCoV, in Q2 2021 Anticipated production of up to 5...
03/03/2021 | Ovesco Endoscopy AG

Analysis of large nationwide FTRD® registry shows 80 % R0-resection rate of difficult adenomas, early carcinomas and subepithelial tumors

Evaluation of the “German colonic FTRD registry” comprising 1178 colorectal FTRD procedures from 65 centers of different care levels demonstrated technical success in 88....

Towards Smart Biofactories: Insilico and Meyer Chroma Technology link Upstream and Downstream Digital Twins for Biologics Production

(Stuttgart) - Insilico Biotechnology AG and Meyer Chroma Technology (MCT) announce joining forces to provide the biopharma industry with an eco-system of Digital Twins en...
02/23/2021 | Ovesco Endoscopy AG

EFTR with the FTRD® System offers alternative to radical surgery for smaller complex colorectal lesions

A prospective multicenter study analyzing the data of the Dutch colorectal eFTR registry comprising 367 EFTR procedures shows a technical success rate of 83.9 % and a R0 ...
02/12/2021 | CureVac AG

CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV

Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV Submission of CVnCoV pre-clinical data package marks start of...

The Digital Healthcare Act – a world first, with opportunities for companies and patients

It may have something of an obscure and unassuming title, but the Digital Healthcare Act (Digitale-Versorgung-Gesetz) makes Germany the first country in the world to intr...
02/10/2021 | Ovesco Endoscopy AG

OTSC® placement in the colon in routine endoscopy: administrative data from large health insurance company shows high safety and efficacy.

Colonic OTSC placement was mostly performed in patients undergoing polypectomy (62.4 %), but also for closure of iatrogenic perforations (15.8 %), colonic bleeding (10.1 ...

Water-repellent and more: coating textiles sustainably with chitosan

Biomolecules from renewable raw materials for the textile industry Textiles can be coated with the biopolymer chitosan and thus made water-repellent by binding hydrophobic molecules. The good thing...
02/05/2021 | CureVac AG

CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

Building an integrated European vaccine manufacturing network with experienced partners Managing supply chain risk by collaborating with several partners for each ma...